Financing through the 10th Series of Stock Acquisition Rights
First written in FY2025. 4 of 6 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-09-08.
1 other company's latest entry also says "Achieved".
- FY2027-H1AdvancedAnnual report
「Cumulative number of such exercise-price-adjustable warrants exercised as of the end of the interim accounting period 52,287 Cumulative shares delivered upon exercise as of the end of the interim accounting period 5,228,700 Cumulative funds raised through exercise as of the end of the interim accounting period (¥ thousand) 661,408」
During the interim accounting period, 987 of the 10th Series Warrants were exercised, delivering 98,700 shares and raising ¥9,870 thousand. Cumulative figures were 52,287 warrants, 5,228,700 shares and ¥661,408 thousand. - FY2026-H1AdvancedAnnual report
「10th Series Warrants: number exercised during the interim accounting period, 51,300; shares delivered upon exercise, 5,130,000; average exercise price during the interim accounting period, ¥127.0; funds raised through exercise, ¥651,538 thousand.」
Of the framework allowing up to 80,000 warrants representing 8,000,000 shares, 51,300 warrants were exercised, delivering 5,130,000 shares and raising ¥651,538 thousand. - FY2025First statedAnnual report
「Pursuant to a Board of Directors resolution dated 14 March 2025, the Company issued on 31 March 2025 the 10th Series Warrants with exercise-price adjustment provisions through a private placement to Growth Capital Co., Ltd. As of the end of the month preceding the filing date, the potential shares represented by these warrants totaled 4,770,000, equivalent to 11.0% of the Company’s 43,560,067 shares issued and outstanding.」
The Company issued the 10th Series Warrants to Growth Capital Co., Ltd. on 31 March 2025, establishing a framework to raise up to ¥1,521,360,000 through a maximum of 8,000,000 shares. Proceeds are intended for the TMS-007 ORION trial, R&D including TMS-008 and working capital.